New study aims to predict which prostate cancer patients benefit from Lu-PSMA therapy

NCT ID NCT06600802

First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 19 times

Summary

This study is looking for genetic clues in tumor tissue that could help doctors know ahead of time whether Lu-PSMA treatment will work for men with advanced, castration-resistant prostate cancer. About 120 men who have already tried other treatments will provide tumor samples for analysis. The goal is to find molecular markers that predict response, so future patients can get the right treatment sooner.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Grenoble

    NOT_YET_RECRUITING

    La Tronche, 38700, France

    Contact

  • Centre Jean PERRIN

    RECRUITING

    Clermont-Ferrand, 63011, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Centre Paul STRAUSS

    NOT_YET_RECRUITING

    Strasbourg, 67091, France

    Contact

  • Hospices Civiles de Lyon

    NOT_YET_RECRUITING

    Pierre-Bénite, 69310, France

    Contact

  • Hôpital privé de la Loire

    NOT_YET_RECRUITING

    Saint-Etienne, 42100, France

    Contact

Conditions

Explore the condition pages connected to this study.